235 related articles for article (PubMed ID: 29560753)
1. Adherence, risk factors of non-adherence and patient's preferred treatment strategy of mesalazine in ulcerative colitis: multicentric observational study.
Keil R; Wasserbauer M; Zádorová Z; Kojecký V; Hlava Š; Št'ovíček J; Chudý J; Roznětinská M; Drábek J; Kubišová N; Lochmannová J
Scand J Gastroenterol; 2018 Apr; 53(4):459-465. PubMed ID: 29560753
[TBL] [Abstract][Full Text] [Related]
2. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.
Flourié B; Hagège H; Tucat G; Maetz D; Hébuterne X; Kuyvenhoven JP; Tan TG; Pierik MJ; Masclee AA; Dewit O; Probert CS; Aoucheta D;
Aliment Pharmacol Ther; 2013 Apr; 37(8):767-75. PubMed ID: 23451806
[TBL] [Abstract][Full Text] [Related]
3. eHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis.
Pedersen N; Thielsen P; Martinsen L; Bennedsen M; Haaber A; Langholz E; Végh Z; Duricova D; Jess T; Bell S; Burisch J; Munkholm P
Inflamm Bowel Dis; 2014 Dec; 20(12):2276-85. PubMed ID: 25248002
[TBL] [Abstract][Full Text] [Related]
4. The impact of MMX mesalazine on disease-specific health-related quality of life in ulcerative colitis patients.
Solomon D; Yarlas A; Hodgkins P; Karlstadt R; Yen L; Kane S
Aliment Pharmacol Ther; 2012 Jun; 35(12):1386-96. PubMed ID: 22536781
[TBL] [Abstract][Full Text] [Related]
5. [Effectiveness of new, once-daily 5-aminosalicylic acid in the treatment of ulcerative colitis].
Lakatos PL; Lakatos L
Orv Hetil; 2009 Mar; 150(9):397-404. PubMed ID: 19228568
[TBL] [Abstract][Full Text] [Related]
6. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.
D'Haens G; Hommes D; Engels L; Baert F; van der Waaij L; Connor P; Ramage J; Dewit O; Palmen M; Stephenson D; Joseph R
Aliment Pharmacol Ther; 2006 Oct; 24(7):1087-97. PubMed ID: 16984503
[TBL] [Abstract][Full Text] [Related]
7. Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis.
Farup PG; Hinterleitner TA; Lukás M; Hébuterne X; Rachmilewitz D; Campieri M; Meier R; Keller R; Rathbone B; Oddsson E
Inflamm Bowel Dis; 2001 Aug; 7(3):237-42. PubMed ID: 11515850
[TBL] [Abstract][Full Text] [Related]
8. Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials.
Lichtenstein GR; Zakko S; Gordon GL; Murthy U; Sedghi S; Pruitt R; Merchant K; Bortey E; Forbes WP
Aliment Pharmacol Ther; 2012 Jul; 36(2):126-34. PubMed ID: 22617015
[TBL] [Abstract][Full Text] [Related]
9. Treatment of new-onset ulcerative colitis and ulcerative proctitis: a retrospective study.
Richter JM; Kushkuley S; Barrett JA; Oster G
Aliment Pharmacol Ther; 2012 Aug; 36(3):248-56. PubMed ID: 22690748
[TBL] [Abstract][Full Text] [Related]
10. Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial.
Raedler A; Behrens C; Bias P
Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1353-63. PubMed ID: 15606398
[TBL] [Abstract][Full Text] [Related]
11. Decision tree construction and cost-effectiveness analysis of treatment of ulcerative colitis with pentasa® mesalazine 2 g sachet.
Nishikawa AM; Paladini L; Delfini R; Kotze PG; Clark O
Arq Gastroenterol; 2013; 50(4):297-303. PubMed ID: 24474233
[TBL] [Abstract][Full Text] [Related]
12. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial.
Kruis W; Kiudelis G; Rácz I; Gorelov IA; Pokrotnieks J; Horynski M; Batovsky M; Kykal J; Boehm S; Greinwald R; Mueller R;
Gut; 2009 Feb; 58(2):233-40. PubMed ID: 18832520
[TBL] [Abstract][Full Text] [Related]
13. Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life.
Probert CS; Dignass AU; Lindgren S; Oudkerk Pool M; Marteau P
J Crohns Colitis; 2014 Mar; 8(3):200-7. PubMed ID: 24012063
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial comparing 4.8 vs. 2.4 g/day of oral mesalazine for maintenance of remission in ulcerative colitis.
Pica R; Cassieri C; Cocco A; Zippi M; Marcheggiano A; De Nitto D; Avallone EV; Crispino P; Occhigrossi G; Paoluzi P
Dig Liver Dis; 2015 Nov; 47(11):933-7. PubMed ID: 26391602
[TBL] [Abstract][Full Text] [Related]
15. Use of new once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis: Is there anything new under the sun?
Lakatos PL
World J Gastroenterol; 2009 Apr; 15(15):1799-804. PubMed ID: 19370774
[TBL] [Abstract][Full Text] [Related]
16. E-health: Web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance.
Elkjaer M
Dan Med J; 2012 Jul; 59(7):B4478. PubMed ID: 22759851
[TBL] [Abstract][Full Text] [Related]
17. Long-term mesalamine maintenance in ulcerative colitis: which is more important? Adherence or daily dose.
Khan N; Abbas AM; Koleva YN; Bazzano LA
Inflamm Bowel Dis; 2013 May; 19(6):1123-9. PubMed ID: 23514878
[TBL] [Abstract][Full Text] [Related]
18. Review article: medication non-adherence in ulcerative colitis--strategies to improve adherence with mesalazine and other maintenance therapies.
Hawthorne AB; Rubin G; Ghosh S
Aliment Pharmacol Ther; 2008 Jun; 27(12):1157-66. PubMed ID: 18384664
[TBL] [Abstract][Full Text] [Related]
19. Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans affairs healthcare system.
Khan N; Abbas AM; Bazzano LA; Koleva YN; Krousel-Wood M
Aliment Pharmacol Ther; 2012 Oct; 36(8):755-64. PubMed ID: 22882428
[TBL] [Abstract][Full Text] [Related]
20. Clinical trial: Effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study.
Hiwatashi N; Suzuki Y; Mitsuyama K; Munakata A; Hibi T
J Gastroenterol; 2011 Jan; 46(1):46-56. PubMed ID: 20878425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
